Lexicon Pharmaceuticals (LXRX) Change in Acquisitions & Divestments (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Change in Acquisitions & Divestments data on file, last reported at $35.7 million in Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments fell 66.18% year-over-year to $35.7 million in Q1 2026; TTM through Mar 2026 was $183.0 million, a 47.25% decrease from a year earlier, with the FY2025 full-year figure at $252.9 million, down 19.57% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $35.7 million, up from $27.0 million in the prior quarter.
• Over the last five years, Change in Acquisitions & Divestments for LXRX reached as high as $105.6 million in Q1 2025 and fell as low as $8.7 million in Q2 2022.
• Historically, Change in Acquisitions & Divestments has averaged $49.5 million across 5 years, with a median of $41.5 million in 2025.
• Across the five-year window, Change in Acquisitions & Divestments soared 447.43% in 2023 and slumped 66.25% in 2025, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $26.0 million in 2022, then soared by 99.95% to $52.0 million in 2023, then surged by 53.85% to $80.0 million in 2024, then slumped by 66.25% to $27.0 million in 2025, then jumped by 32.21% to $35.7 million in 2026.
• Per Business Quant data, the three most recent Change in Acquisitions & Divestments figures were $35.7 million in Q1 2026, $27.0 million in Q4 2025, and $78.8 million in Q3 2025.